In vivo Evaluation of C. difficile Enoyl-ACP Reductase II (FabK) Inhibition by Phenylimidazole Unveils a Promising Narrow-Spectrum Strategy for CDI Therapeutics
FabK is the sole ENR reductase in C. difficile. Fecal microbiota investigation of Mus musculus on the treatment with vancomycin, fidaxomicin, and phenylimidazole analog 296 was done with the purpose of confirming it to be a promising narrow-spectrum therapeutic target to particularly inhibit C. difficile.